Andrew J Armstrong

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. ncbi request reprint A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer
    Andrew J Armstrong
    Duke Cancer Institute and the Duke Prostate Center, Duke University, Durham NC Department of Medicine, Division of Medical Oncology, Duke University, Durham NC Department of Surgery, Division of Urology, Duke University, Durham NC Duke University Medical Center, Duke University, Durham NC Electronic address
    Clin Genitourin Cancer 11:397-406. 2013
  2. doi request reprint Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin
    Andrew J Armstrong
    Divisions of Medical Oncology and Urology, Department of Medicine, Duke Cancer Institute, Duke University Medical Center, Box 102002, Durham, NC 27710, USA
    J Clin Oncol 30:3402-7. 2012
  3. pmc Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer
    Andrew J Armstrong
    Duke Cancer Institute and the Duke Prostate Center, Duke University, Durham, NC 27710, USA
    Eur Urol 61:549-59. 2012
  4. ncbi request reprint Systemic strategies for prostate cancer
    A J Armstrong
    Duke Prostate Center, Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, NC, USA
    Minerva Urol Nefrol 59:11-25. 2007
  5. doi request reprint Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer
    Andrew J Armstrong
    Department of Medicine, Division of Medical Oncology, Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, North Carolina 102002, USA
    Clin Cancer Res 16:203-11. 2010
  6. doi request reprint The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer
    A J Armstrong
    Duke Comprehensive Cancer Center, Duke University, Durham, NC 27705, USA
    Prostate Cancer Prostatic Dis 12:88-93. 2009
  7. doi request reprint New drug development in metastatic prostate cancer
    Andrew J Armstrong
    Division of Medical Oncology, Department of Medicine, Duke Comprehensive Cancer Center, DUMC, Durham, NC 27705, USA
    Urol Oncol 26:430-7. 2008
  8. ncbi request reprint Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature
    Andrew J Armstrong
    Department of Medicine and Surgery, Duke Comprehensive Cancer Center, Durham, NC 27710, USA
    Oncologist 14:816-27. 2009
  9. ncbi request reprint Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer
    A J Armstrong
    Duke Prostate Center, Durham, NC, USA
    Prostate Cancer Prostatic Dis 13:108-16. 2010
  10. doi request reprint The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival
    Andrew J Armstrong
    Division of Medical Oncology, Department of Medicine, DUMC, Duke Comprehensive Cancer Center and the Duke Prostate Center, Durham, NC 27715, USA
    Eur J Cancer 46:517-25. 2010

Collaborators

Detail Information

Publications41

  1. ncbi request reprint A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer
    Andrew J Armstrong
    Duke Cancer Institute and the Duke Prostate Center, Duke University, Durham NC Department of Medicine, Division of Medical Oncology, Duke University, Durham NC Department of Surgery, Division of Urology, Duke University, Durham NC Duke University Medical Center, Duke University, Durham NC Electronic address
    Clin Genitourin Cancer 11:397-406. 2013
    ..Temsirolimus blocks mammalian target of rapamycin (mTOR)/target of rapamycin complex 1 (TORC1), a key signaling node in this pathway; its activity in men with advanced castration-resistant metastatic prostate cancer (mCRPC) is unknown...
  2. doi request reprint Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin
    Andrew J Armstrong
    Divisions of Medical Oncology and Urology, Department of Medicine, Duke Cancer Institute, Duke University Medical Center, Box 102002, Durham, NC 27710, USA
    J Clin Oncol 30:3402-7. 2012
    ..We tested whether serum LDH is prognostic and has predictive value in patients with metastatic RCC receiving an mTOR inhibitor...
  3. pmc Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer
    Andrew J Armstrong
    Duke Cancer Institute and the Duke Prostate Center, Duke University, Durham, NC 27710, USA
    Eur Urol 61:549-59. 2012
    ....
  4. ncbi request reprint Systemic strategies for prostate cancer
    A J Armstrong
    Duke Prostate Center, Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, NC, USA
    Minerva Urol Nefrol 59:11-25. 2007
    ..The collection of tumor or surrogate tissue is emphasized to define biomarkers that may predict for sensitivity to these systemic therapies...
  5. doi request reprint Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer
    Andrew J Armstrong
    Department of Medicine, Division of Medical Oncology, Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, North Carolina 102002, USA
    Clin Cancer Res 16:203-11. 2010
    ..We sought to evaluate predictors of overall survival following progression after systemic chemotherapy in men with metastatic castration-resistant prostate cancer...
  6. doi request reprint The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer
    A J Armstrong
    Duke Comprehensive Cancer Center, Duke University, Durham, NC 27705, USA
    Prostate Cancer Prostatic Dis 12:88-93. 2009
    ..There was evidence of potential hemodilution of PSA and alkaline phosphatase levels in obese men...
  7. doi request reprint New drug development in metastatic prostate cancer
    Andrew J Armstrong
    Division of Medical Oncology, Department of Medicine, Duke Comprehensive Cancer Center, DUMC, Durham, NC 27705, USA
    Urol Oncol 26:430-7. 2008
    ....
  8. ncbi request reprint Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature
    Andrew J Armstrong
    Department of Medicine and Surgery, Duke Comprehensive Cancer Center, Durham, NC 27710, USA
    Oncologist 14:816-27. 2009
    ....
  9. ncbi request reprint Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer
    A J Armstrong
    Duke Prostate Center, Durham, NC, USA
    Prostate Cancer Prostatic Dis 13:108-16. 2010
    ..In this review we address these topics in light of prognostic and predictive factors to help guide the rational use of docetaxel chemotherapy in men with this aggressive disease...
  10. doi request reprint The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival
    Andrew J Armstrong
    Division of Medical Oncology, Department of Medicine, DUMC, Duke Comprehensive Cancer Center and the Duke Prostate Center, Durham, NC 27715, USA
    Eur J Cancer 46:517-25. 2010
    ....
  11. ncbi request reprint A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis
    Andrew J Armstrong
    Duke Comprehensive Cancer Center, Durham, North Carolina 27705, USA
    Clin Cancer Res 13:6396-403. 2007
    ..To develop a prognostic model and nomogram using baseline clinical variables to predict death among men with metastatic hormone-refractory prostate cancer (HRPC)...
  12. ncbi request reprint Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer
    Andrew J Armstrong
    Duke Comprehensive Cancer Center, Durham, NC 27710, USA
    J Clin Oncol 25:3965-70. 2007
    ..Here we examined various degrees of PSA decline and pain response as surrogates for the survival benefit observed in the TAX327 trial...
  13. pmc Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers
    Andrew J Armstrong
    Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Mol Cancer Res 9:997-1007. 2011
    ....
  14. pmc A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer
    Andrew J Armstrong
    Duke Comprehensive Cancer Center and Duke Prostate Center, Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina 27710, USA
    Clin Cancer Res 16:3057-66. 2010
    ....
  15. doi request reprint A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer
    Andrew J Armstrong
    Duke Prostate Center, 2424 Erwin Road, Durham, NC 27705, USA
    Clin Cancer Res 14:6270-6. 2008
    ....
  16. pmc Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy
    Susan Halabi
    Affiliations of authors Department of Biostatistics and Bioinformatics, SH, c yl, EK, and Alliance Statistics and Data Center SH, Duke University, Durham, NC Departments of Medicine and Urology, University of California San Francisco, San Francisco, CA EJS Division of Medical Oncology, Duke Prostate Center and the Duke Cancer Institute, Durham, NC AJA Departments of Medical Oncology and Urology, Yale University Cancer Center, New Haven, CT DP Department of Medical Oncology, San Camillo and Forlanini Hospital, Rome, Italy CNS Sanofi, Malvern, PA LS Department of Medical Oncology, Georges Pompidou European Hospital, Paris, France SO Department of Clinical Studies, Royal Marsden Hospital and Institute of Cancer Research, Surrey, United Kingdom JdB Urology Department, Tulane Cancer Center, New Orleans, LA OS
    J Natl Cancer Inst 105:1729-37. 2013
    ..We sought to develop and validate a prognostic model to predict OS in men who had progressed after first-line chemotherapy and were selected to receive second-line chemotherapy...
  17. doi request reprint Clinical endpoints for drug development in prostate cancer
    Veshana Ramiah
    Duke Prostate Center, Durham, North Carolina, USA
    Curr Opin Urol 18:303-8. 2008
    ..This review highlights many of the current potential early measures of response and clinical benefit that are worthy of future study and validation in this disease...
  18. ncbi request reprint Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors
    James D Turnbull
    Duke Cancer Institute, Duke University Medical Center, Durham, NC 27710, USA
    Clin Genitourin Cancer 11:45-50. 2013
    ....
  19. pmc Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy
    Susan Halabi
    Susan Halabi, Andrew J Armstrong, Ellen Kaplan, Chen Yen Lin, and Nicole C Solomon, Duke University, Durham, NC Oliver Sartor, Tulane University, New Orleans, LA Johann de Bono, Royal Marsden Hospital, Sutton, United Kingdom and Eric J Small, University of California at San Francisco, San Francisco, CA
    J Clin Oncol 31:3944-50. 2013
    ..The objective of this analysis was to evaluate post-treatment PSA kinetics as surrogates for OS in patients receiving second-line chemotherapy...
  20. ncbi request reprint A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer
    Young E Whang
    Division of Hematology Oncology, Department of Medicine, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Urol Oncol 31:82-6. 2013
    ..Lapatinib is an oral inhibitor of EGFR and HER-2. The objective of this study is to assess the preliminary clinical efficacy of lapatinib in the therapy of castration-resistant prostate cancer...
  21. pmc Development of a method to isolate circulating tumor cells using mesenchymal-based capture
    Rhonda L Bitting
    Division of Medical Oncology, Duke Cancer Institute, Duke University, Durham, NC, United States Department of Medicine, Duke University, Durham, NC, United States Center for RNA Biology, Duke University, Durham, NC, United States
    Methods 64:129-36. 2013
    ..This method may complement existing epithelial-based methods and may be particularly useful in patients with bone metastases. ..
  22. ncbi request reprint A Phase Ib Study of Combined VEGFR and mTOR Inhibition With Vatalanib and Everolimus in Patients With Advanced Renal Cell Carcinoma
    Rhonda L Bitting
    Duke Cancer Institute, Duke University Medical Center, Durham, NC
    Clin Genitourin Cancer 12:241-50. 2014
    ..Combination therapy with VEGFR and mTOR inhibitors has not been well tolerated to date but may have efficacy in renal cell carcinoma (RCC)...
  23. doi request reprint Potential predictive biomarkers for individualizing treatment for men with castration-resistant prostate cancer
    Rhonda L Bitting
    Duke Cancer Institute and the Duke Prostate Center, Durham, NC 27710, USA
    Cancer J 19:25-33. 2013
    ..There are currently no validated predictive biomarkers in CRPC. We discuss potential predictive biomarkers in men with CRPC and how these may be developed in the context of therapeutic clinical trials...
  24. doi request reprint Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy
    Gregory R Pond
    Department of Oncology, McMaster University and Ontario Clinical Oncology Group, Hamilton, Ontario, Canada
    BJU Int 110:E461-8. 2012
    ..Prospective validation is warranted...
  25. ncbi request reprint Therapy for non-clear cell histologies in renal cancer
    Rhonda L Bitting
    Department of Medicine, Division of Medical Oncology, Duke University and the Duke Cancer Institute, Durham, NC 27710, USA
    Curr Clin Pharmacol 6:169-80. 2011
    ..Controlled studies in these relatively rare subgroups are needed to inform upon clinical practice which is currently based on small series of uncontrolled studies. Ongoing clinical trials and areas of future research will be discussed...
  26. ncbi request reprint Inertial properties and loading rates affect buckling modes and injury mechanisms in the cervical spine
    R W Nightingale
    Department of Biomedical Engineering, Duke University, Durham, NC 27708 0281, USA
    J Biomech 33:191-7. 2000
    ..Injury types and mechanisms may be substantially altered by loading rate because inertial effects may influence whether the cervical spine fails in a compressive mode, or a bending mode...
  27. ncbi request reprint The role of surrogate markers in the management of men with metastatic castration-resistant prostate cancer
    Andrew J Armstrong
    Divisions of Medical Oncology and Urology, Duke Cancer Institute and the Duke Prostate Center, Durham, North Carolina, USA
    Clin Adv Hematol Oncol 9:1-14; quiz 15-6. 2011
    ..Many potential biomarkers have been identified, often from studies showing their prognostic potential. In this roundtable, experts discuss the role of biomarkers in measuring response to immunotherapy for men with mCRPC...
  28. ncbi request reprint The role of epithelial plasticity in prostate cancer dissemination and treatment resistance
    Rhonda L Bitting
    Division of Medical Oncology, Duke Cancer Institute, Duke University, DUMC Box 102002, Durham, NC, 27710, USA
    Cancer Metastasis Rev 33:441-68. 2014
    ....
  29. doi request reprint Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer
    Rhonda L Bitting
    Division of Medical Oncology, Duke Cancer Institute, Duke University, DUMC Box 102002, Durham, North Carolina 27710, USA
    Endocr Relat Cancer 20:R83-99. 2013
    ..Here, we review the role of the PI3K/Akt/mTOR pathway in prostate cancer and discuss the potential use of pathway inhibitors as single agents or in combination in the evolving treatment landscape of castration-resistant prostate cancer...
  30. ncbi request reprint Cell signaling modifiers in prostate cancer
    Franklin L Chen
    Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Cancer J 14:40-5. 2008
    ..Further investigation is necessary for the targeted inhibition of receptor tyrosine kinases and mTOR in HRPC. However, these classes of drugs may prove efficacious as tumoricidal agents or as chemo- and radiosensitizers...
  31. ncbi request reprint Clinical phenotypes of castration-resistant prostate cancer
    Tian Zhang
    Duke Cancer Institute, Durham, North Carolina
    Clin Adv Hematol Oncol 11:707-18. 2013
    ..We then address the potential relationship between these clinical phenotypes (with their underlying molecular subtypes) and therapeutic decision- making and prognosis, as well as ongoing research strategies...
  32. ncbi request reprint Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes
    Rahul Aggarwal
    From the aDepartment of Medicine, Division of Hematology Oncology, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, and Department of Medicine, and bDepartment of Medicine, Division of Medical Oncology, Duke Cancer Institute, Durham, North Carolina
    J Natl Compr Canc Netw 12:719-26. 2014
    ....
  33. pmc Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease
    Michael R Harrison
    Duke Cancer Institute, Durham, NC, USA
    Cancer Manag Res 5:1-14. 2013
    ..When compared with beta-emitters (eg, strontium-89, samarium-153), (223)Ra delivers a high quantity of energy per track length with short tissue penetration...
  34. doi request reprint Utilization trends at a multidisciplinary prostate cancer clinic: initial 5-year experience from the Duke Prostate Center
    Suzanne Biehn Stewart
    Division of Urology, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Urol 187:103-8. 2012
    ....
  35. ncbi request reprint Novel therapeutic approaches to advanced prostate cancer
    Andrew J Armstrong
    Johns Hopkins School of Medicine, Baltimore, MD 21231, USA
    Clin Adv Hematol Oncol 3:271-82. 2005
    ..Clinical advances in meaningful endpoints such as survival and quality of life are eagerly awaited in large-scale trials of active and rationally designed agents...
  36. ncbi request reprint Chemotherapy for advanced prostate cancer: results of new clinical trials and future studies
    Andrew J Armstrong
    Prostate Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, CRB 1M88, 1650 Orleans Street, Baltimore, MD 21231, USA
    Curr Oncol Rep 7:220-7. 2005
    ..The role of chemotherapy for advanced disease in the neoadjuvant or adjuvant setting, in biochemically (PSA) relapsed patients, and as second-line therapy for relapsed disease, remains a subject of active clinical investigation...
  37. ncbi request reprint New drugs in prostate cancer
    Andrew J Armstrong
    Prostate Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, 1650 Orleans Street, Baltimore, MD 21231, USA
    Curr Opin Urol 16:138-45. 2006
    ....
  38. ncbi request reprint Anti-angiogenic therapy in renal cell cancer
    Ramaprasad Srinivasan
    Urologic Oncology Branch, Center for Cancer Research, Division of Cancer Prevention, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA
    BJU Int 99:1296-300. 2007
    ..However, to what extent the clinical benefit of anti-angiogenic strategies in RCC can be built upon is unknown...
  39. doi request reprint Re: Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens
    Andrew J Armstrong
    J Natl Cancer Inst 100:681-2; author reply 682-3. 2008
  40. ncbi request reprint Advanced prostate cancer: the future
    Andrew J Armstrong
    Prostate Cancer Research Program, Johns Hopkins School of Medicine, Baltimore, MD 21231, USA
    Can J Urol 12:42-7. 2005
    ..Novel approaches including novel cytotoxics, immunotherapy, PSMA targeted monoclonal antibodies are among the broad categories that will be discussed in this brief review...